Page last updated: 2024-12-07

2-methoxyestriol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-Methoxyestriol is a synthetic estrogen that is a metabolite of estriol. It has been studied for its potential therapeutic effects in a variety of conditions, including menopausal symptoms, osteoporosis, and Alzheimer's disease. 2-Methoxyestriol is a potent estrogen agonist, meaning that it binds to estrogen receptors and activates them. This activation can lead to a variety of effects, including the stimulation of bone growth, the reduction of cholesterol levels, and the improvement of cognitive function. However, 2-methoxyestriol also has some potential side effects, such as increased risk of blood clots and breast cancer. More research is needed to fully understand the risks and benefits of 2-methoxyestriol.'

Cross-References

ID SourceID
PubMed CID102031
CHEMBL ID1908077
SCHEMBL ID1234696
MeSH IDM0151796

Synonyms (17)

Synonym
2-methoxyestriol
2-meoe3
estra-1,3,5(10)-triene-3,16,17-triol, 2-methoxy-, (16alpha,17beta)-
(8r,9s,13s,14s,16r,17r)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol
2-methoxyoestradiol-bis-sulphamate
1236-72-2
2-methoxyestriol-bis-sulphamate
2-methoxyestriol-bis-sulfamate
CHEMBL1908077
SCHEMBL1234696
2-methoxyestra-1,3,5(10)-triene-3,16,17-triol #
PEXPJFWTSZLEAQ-YSYMNNNUSA-N
estra-1,3,5(10)-triene-3,16,17-triol, 2-methoxy-, (16.alpha.,17.beta.)-
(8r,9s,13s,14s,16r,17r)-2-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthrene-3,16,17-triol
2-methoxyestra-1(10),2,4-triene-3,16,17-triol
DTXSID60924551
1,3,5(10)-estratrien-2,3,16alpha,17beta-tetrol 2-methyl ether

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In the present study, we have compared the pharmacokinetic profiles and metabolism of 2-MeOE2 and its sulphamoylated derivative, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bisMATE), in adult female rats."( Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
Chander, SK; Ireson, CR; Leese, MP; Newman, SP; Parish, D; Perera, S; Potter, BV; Purohit, A; Reed, MJ; Smith, AC, 2004
)
0.32

Compound-Compound Interactions

ExcerptReferenceRelevance
" In conclusion, 2ME, alone or in combination with TRAIL, may be an effective treatment for cancers of uterine origin with minimal toxicity to corresponding healthy female reproductive tissue."( The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium.
Brañes, J; Brosens, JJ; Cuello, M; Kato, S; Lange, S; Owen, GI; Sadarangani, A; Villalón, M, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" Thus, the bioavailability of 2-MeOE2 is very low, whereas for 2-MeOE2bisMATE it was 85%."( Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
Chander, SK; Ireson, CR; Leese, MP; Newman, SP; Parish, D; Perera, S; Potter, BV; Purohit, A; Reed, MJ; Smith, AC, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (33.33)18.7374
1990's2 (13.33)18.2507
2000's5 (33.33)29.6817
2010's3 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.62 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (13.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]